Opella is Sanofi’s consumer healthcare business unit focusing on over-the-counter medicines, vitamins, minerals, and supplements and includes brands such as Allegra, Doliprane, and Dulcolax.

Together, CD&R and Sanofi will support Opella’s growth strategy as a pure-play, global, and fast-moving consumer healthcare company ... With a portfolio of iconic brands, such as Allegra ...

Sanofi and CD&R partner to ... to create a French-headquartered, global consumer healthcare champion. Opella is differentiated by the quality of its brand portfolio and its highly skilled and ...

Sanofi and CD&R enter exclusive negotiations ... innovation and growth to create a French-headquartered, global consumer healthcare champion. Opella is differentiated by the quality of its brand ...

Sanofi and CD&R enter exclusive negotiations ... innovation and growth to create a French-headquartered, global consumer healthcare champion. Opella is differentiated by the quality of its brand ...

With a portfolio of brands, such as Allegra ... reportedly raised its bid for Sanofi’s consumer health division by around 200 million euros ($217.12 million). While CD&R has emerged as the ...

Together, CD&R and Sanofi will support Opella’s growth strategy as a pure-play, global, and fast-moving consumer healthcare company ... With a portfolio of iconic brands, such as Allegra, Doliprane, ...

Sanofi and CD&R are joining forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion ... With a portfolio of iconic brands, such as Allegra, Doliprane ...